ImpriMed

ImpriMed is a biotechnology company that uses artificial intelligence (AI) to help healthcare providers predict drug responses for cancer and other diseases in dogs. ImpriMed’s technology has been used in over 40 U.S. states and has performed over 15,000 canine and feline blood cancer tests as of 2023. ImpriMed’s flagship offering, the Personalized Prediction Profile, has aided more than 5,000 dogs afflicted with lymphoma and leukemia under the guidance of board-certified veterinary oncologists.